Supernus Pharmaceuticals Inc
Supernus Stock Shows Promise in the ADHD Drug Market
A Financial Overview of Supernus Pharmaceuticals in September
In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.
Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”
Analyzing BEAT, SUPN, ADBE And RHT Stocks
Growth stock analysis BioTelemetry BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market […]
Total Returns and Sector Exposure for Growth Indexes
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).
Here’s What Drove Supernus Pharmaceuticals Stock in March 2018
Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018.
A Comparative Analysis of PTH and DWAQ
PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.
An Overview of PTH’s Pharmaceutical and Biotechnology Holdings
PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.
On a Bullish Day, IBB Outperformed XLV
The iShares Nasdaq Biotechnology ETF (IBB) rose 4.4%, the Health Care Select Sector SPDR ETF (XLV) rose 2.2%, and the SPDR S&P 500 ETF (SPY) moved up by 1.5% on October 15.